Cerebrolysin
Porcine brain-derived neuropeptide preparation containing bioactive peptide fragments of neurotrophic factors, used clinically in over 40 countries for stroke recovery, traumatic brain injury, and cognitive impairment
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Suggested dose
10 mL – 50 mL
Compound profile
Scientific & efficacy data
Cognitive
Peptide profile
Moderate human trials
Cerebrolysin
10 mL · Once daily
Molecular formula
Complex mixture — no single molecular formula (contains multiple peptide fragments and free amino acids derived from porcine brain proteins)
- Mol. weight
- Bioactive peptide components are all below 10 kDa (10,000 Da); the preparation contains a spectrum of peptide sizes
- CAS number
- Not assigned (biological mixture)
- PubChem
- Not available (complex biological preparation)
- Developed · Research ongoing
- Academic research consortium
Multiple research institutions
Amino acid sequence
Complex mixture of peptide fragments derived from BDNF, GDNF, NGF, CNTF, IGF-1, IGF-2, and other neurotrophic factors — no single amino acid sequenceStroke Recovery
Clinical trials show improved movement and thinking skills after stroke, with brain-protective effects that help damaged neurons survive and rebuild connections [2][13].
Alzheimer's Support
Over 30 years of clinical use shows modest improvements in memory and daily function for people with Alzheimer's, though results vary between patients [1].
Dosing
How much do I take?
10 mL – 50 mL · once daily · intravenous
10 mL – 50 mL
Once daily
Covers all 4 documented dose levels · 2 administration routes · timing · dose-adjustment guidance.
Suitability
Is this right for me?
Best for post-stroke neurorecovery and rehabilitation support & cognitive support in alzheimer's disease and vascular dementia
Best for
Post-stroke neurorecovery and rehabilitation support
Cerebrolysin is particularly well-suited for individuals focused on post-stroke neurorecovery and rehabilitation support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [2][13].
Cognitive support in Alzheimer's disease and vascular dementia
Cerebrolysin is particularly well-suited for individuals focused on cognitive support in alzheimer's disease and vascular dementia. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][6].
Traumatic brain injury recovery and neuroprotection
Cerebrolysin is particularly well-suited for individuals focused on traumatic brain injury recovery and neuroprotection. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [14].
Age-related cognitive decline and mild cognitive impairment
Cerebrolysin is particularly well-suited for individuals focused on age-related cognitive decline and mild cognitive impairment. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1].
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Cerebrolysin with similar peptides to find the best fit for your goals.
Administration
How do I use it?
Intravenous (IV) injection or infusion · Intramuscular (IM) injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is it safe?
6 common side effects · 2 serious
Cerebrolysin is an FDA-unregulated neuroprotective agent consisting of porcine brain-derived peptides and amino acids that has been used primarily in Eastern Europe and Asia.
[8][12] Safety data is limited to observational clinical use and small open-label trials rather than rigorous randomized controlled trials with formal safety monitoring.
As a complex mixture of undefined peptide fragments from animal sources, batch consistency and sterility cannot be guaranteed without pharmaceutical manufacturing standards.
Potential allergic reactions to porcine proteins and transmissible spongiform encephalopathy (TSE) risks from animal-derived components have not been adequately ruled out.
Evidence consists of observational clinical use spanning several decades in European and Asian markets, supplemented by small clinical trials (n<200) that are generally open-label or poorly controlled.
[8][9] No Phase 1 dose-escalation studies, formal toxicology assessments, or Phase 3 randomized trials have been conducted by Western regulatory standards. Published safety data is limited and primarily in non-English journals with methodological limitations.
Common side effects · experienced by some users
Injection site reactions
Cerebrolysin is administered as an IM or IV injection of a porcine brain-derived peptide solution. [10][11] Local reactions (pain, redness, swelling) occur in 5-15% of patients, particularly with IM administration. Reactions are typically mild to moderate, localized to the injection area, and resolve within 24-48 hours. More common with higher volumes (>10 ml) or faster infusion rates. Incidence increases with repeated injections at the same site.
Management: Rotate injection sites for IM administration to different locations (deltoid, gluteal). For IV administration, use large-bore IV catheter in forearm or antecubital fossa to minimize local irritation. Apply warm compress (not ice) to injection site if soreness develops. Topical analgesic cream may help. Reactions typically resolve without intervention within 24-48 hours.
Headache
Headache is reported in 10-15% of patients treated with Cerebrolysin, typically mild to moderate intensity. Usually occurs during or within 1-2 hours of IV infusion. Most commonly occurs with standard (10-30 ml) or higher doses. Mechanism unclear but may relate to hemodynamic changes or rapid blood-brain barrier penetration of neurotrophic peptides. Characteristically responds to standard analgesics and resolves within 2-4 hours.
Management: Usually transient and self-resolving within 2-4 hours. Acetaminophen (500-1000 mg) or ibuprofen (400 mg) may be administered. Reducing the IV infusion rate (give over 30-60 minutes rather than faster) significantly reduces incidence. Ensure adequate hydration before and during infusion. Headache on subsequent injections often decreases or disappears.
Dizziness and vertigo
Dizziness or mild vertigo is reported in 3-8% of Cerebrolysin patients, typically occurring within 30 minutes of IV administration. Episodes are usually brief (15-60 minutes) and self-limited. Related to transient hemodynamic effects or rapid CNS peptide influx across blood-brain barrier. More common with rapid infusion rates or doses >20 ml. [10][11][24] Vertigo (sensation of room spinning) is less common than simple dizziness.
Management: Rest in supine or semi-recumbent position until symptoms resolve. Avoid driving or operating machinery for 2-4 hours after infusion. Slow the IV infusion rate—administering over 30-60 minutes rather than rapid injection markedly reduces dizziness incidence. Ensure adequate hydration and avoid rapid position changes. Symptoms typically subside without specific treatment within 15-60 minutes.
Nausea and gastrointestinal discomfort
Nausea occurs in approximately 3-5% of Cerebrolysin patients, usually mild and transient. May be accompanied by mild stomach discomfort or mild appetite suppression. [11] More common with IM administration than IV. Usually occurs within 30 minutes of injection and resolves within 1-2 hours. Mechanism likely relates to the peptide mixture stimulating GI sensory neurons or mild hemodynamic effects.
Management: Administer with the patient in a comfortable supine or semi-recumbent position. Ensure adequate hydration before and after injection. Slow IV infusion rate reduces incidence significantly. Small frequent meals rather than large meals during treatment course. Ginger tea or peppermint may help symptomatically. Symptoms are usually brief and self-limiting without specific treatment; rarely requires antiemetic medications.
Agitation or restlessness
Agitation or restlessness occurs in approximately 2-4% of patients, more commonly at doses >20 ml or with IV administration. Characterized by nervousness, inability to sit still, or mild irritability lasting 30 minutes to 2 hours after injection. May relate to cholinergic stimulation by neuropeptide fragments or enhanced neuronal activation. More common when Cerebrolysin is given late in the day. [10][11]
Management: More common at higher doses—consider dose reduction if significant. Administer earlier in the morning (before 2 PM) to avoid sleep disruption at night. Patients can engage in calm, low-stimulation activities during treatment period. If agitation is bothersome, healthcare provider may recommend dose reduction or slower infusion. Symptoms typically resolve without specific intervention within 1-4 hours.
Fever
Fever occurs in approximately 1-3% of Cerebrolysin patients, typically low-grade (38-38.5°C / 100.4-101.3°F) and transient. Usually occurs 2-4 hours after injection and resolves spontaneously within 4-8 hours. Mechanism likely represents immune response to foreign porcine proteins or pyrogenic contaminants. [10][11] Higher incidence with IM administration and higher doses. Fever on repeated injections often decreases in frequency and severity.
Management: Monitor body temperature during treatment course. Low-grade fever (<38.5°C) typically requires no specific treatment and resolves without intervention. Acetaminophen (500-1000 mg) or ibuprofen (400 mg) may reduce discomfort if desired. Ensure adequate hydration. If fever is persistent (>8 hours), high-grade (>39°C), or accompanied by other systemic symptoms, evaluate for alternative causes (infection, etc.). Fever on repeat injections usually decreases or disappears.
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Cerebrolysin
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Cerebrolysin should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
With medications
- Safe:Blood thinners (warfarin, heparin) — Monitor closely if combining with Cerebrolysin as interactions may affect bleeding risk or drug metabolism.
With supplements
- Safe:Multivitamins — Generally safe to take alongside Cerebrolysin. Space doses apart if taking oral formulations to ensure optimal absorption.
- Safe:Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
How do I know it's working?
Moderate human trials · first signs days 1-5
Evidence level
Moderate human trials
(Phase 1-2)
Regulatory status
Research compound
Onset of effects
Moderate
(1-2 weeks)
How it works
The deeper mechanism
Cerebrolysin contains bioactive peptide fragments that mimic the activity of neurotrophic factors (BDNF, GDNF, NGF, CNTF).
[16][17] These fragments activate Trk receptors and downstream signaling pathways including PI3K/AKT and MAPK/ERK cascades, promoting neuronal survival, dendritic branching, and synaptogenesis.
[21] The preparation reduces excitotoxicity by modulating glutamate receptor activity and intracellular calcium levels.
[2][17] It also polarizes microglia from the pro-inflammatory M1 phenotype to the neuroprotective M2 phenotype through toll-like receptor modulation, thereby reducing neuroinflammation. [18][19][20] The low molecular weight peptides cross the blood-brain barrier, allowing direct CNS access.
[12][20] Additionally, Cerebrolysin upregulates VEGF expression to promote angiogenesis in ischemic regions, restoring cerebral blood flow. [16]
What to expect
Days 1-5
What you might notice
- Acute neuroprotective effects begin as bioactive peptides cross the blood-brain barrier and activate neurotrophic signaling pathways
- In acute stroke or TBI settings, early neuroprotection against ongoing ischemic damage occurs
- Some patients report improved alertness or reduced confusion
What's normal
- Initial response to Cerebrolysin is beginning at the cellular level
- Different individuals experience Cerebrolysin's onset at different rates
- Transient systemic effects from initial Cerebrolysin exposure are common
What's next
- Maintain consistent Cerebrolysin administration as prescribed
- Document subjective effects and physical markers daily
- Schedule a check-in with your provider about initial observations
Days 5-21
What you might notice
- Neurorestorative processes are actively stimulated including neurogenesis, synaptogenesis, and angiogenesis in damaged brain regions
- Measurable improvements in cognitive function, motor recovery, or speech may become apparent
- This phase corresponds to the standard treatment course duration
What's normal
- Cerebrolysin is achieving sufficient receptor engagement
- Initial mechanism of Cerebrolysin is taking effect
- Early transient effects from Cerebrolysin administration are resolving
What's next
- Maintain consistent Cerebrolysin administration as prescribed
- Document subjective effects and physical markers daily
- Schedule a check-in with your provider about initial observations
Weeks 3-8
What you might notice
- Therapeutic effects continue to develop and consolidate after the treatment course ends
- The neurotrophic and neuroplastic changes initiated during treatment produce ongoing functional improvements
- Clinical studies demonstrate that benefits persist and may continue to increase for weeks after the last injection
What's normal
- Cerebrolysin is now achieving steady-state pharmacokinetics
- Measurable changes aligned with Cerebrolysin's mechanism may appear
- Initial adjustment effects typically resolve by this point
What's next
- Maintain Cerebrolysin dosing exactly as established
- Track progress toward intended outcomes in detail
- Review lab work or biomarker changes with your healthcare team
Months 2-6+
What you might notice
- Sustained improvements in cognitive function and neurological status can persist for months
- For chronic conditions such as Alzheimer's disease, repeat treatment courses at 2-3 month intervals may be recommended to maintain and build upon therapeutic gains
- Long-term studies show that repeated courses can produce cumulative benefits
What's normal
- Full therapeutic effects of Cerebrolysin are well-characterized at this point
- Maintenance of Cerebrolysin's therapeutic effects is typical
- Tolerance patterns with Cerebrolysin are generally stable over months
What's next
- Comprehensive assessment of Cerebrolysin efficacy should be conducted
- Discuss long-term continuation, cycling, or protocol modifications
- Continue regular monitoring of relevant biomarkers or symptoms
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Cerebrolysin over time
- Reduction in symptom frequency or severity
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
Key research
Clinical trials
Tested in people
53 registered studies, 7 still enrolling.
By phase
A trial spanning two phases is counted in both, so these can sum above the total. Observational studies carry no phase.
What kind of research
About 6,394 people took part in the studies that actually administered Cerebrolysin. Observational studies analyse the records of people already taking it — nobody was given anything for the study, so they are counted separately and cannot show cause and effect.
Most recent
Cerebrolysin After Reperfusion in Extended-window EndoVascular Thrombectomy
Chang Gung Memorial Hospital
FSNANO28012025
Foundation For The Study Of Nanoneuroscience And Neuroregeneration
Safety and Feasibility of Using Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage - a Prospective Randomized Open Blinded End-point Trial
Cardinal Stefan Wyszynski University
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered twice is counted once. A study is counted when Cerebrolysin is named as an intervention; studies that only mention it in passing are not.
Questions
Frequently asked
What exactly is Cerebrolysin made from?
Cerebrolysin is produced by controlled enzymatic proteolysis (breakdown) of purified porcine (pig) brain proteins. [22] The manufacturing process, developed by EVER Pharma in Austria, yields a standardized solution containing approximately 25% low molecular weight bioactive peptides and 75% free amino acids. [10][23] The peptide fragments include active sequences derived from several key neurotrophic factors including BDNF, GDNF, NGF, CNTF, IGF-1, and IGF-2. [16][17] Each milliliter contains 215.2 mg of Cerebrolysin concentrate in sterile aqueous solution. [10][11]
Is Cerebrolysin available in the United States?
No, Cerebrolysin is not FDA approved and is not commercially available in the United States. [12] However, it is approved and widely used in over 40 countries across Europe, Asia, and Latin America for the treatment of stroke, traumatic brain injury, Alzheimer's disease, and vascular dementia. [10][12] It has been in clinical use since the 1970s and has an established safety record in those markets.
How is Cerebrolysin administered?
Cerebrolysin is administered exclusively by injection — either intramuscularly (IM) for doses up to 5 ml, or intravenously (IV) for larger doses. [10][11] Doses up to 10 ml can be given as a slow IV injection, while doses above 10 ml must be diluted in physiological saline and administered as an IV infusion over 15-60 minutes. [10][11] Administration should be performed by qualified healthcare professionals. Cerebrolysin is not available in oral form.
What conditions is Cerebrolysin used to treat?
Cerebrolysin is approved in various countries for the treatment of ischemic stroke (20-50 ml/day), traumatic brain injury (20-50 ml/day), Alzheimer's disease (10-30 ml/day), vascular dementia, and age-related cognitive impairment. [10][11] Additional clinical research has explored its use in subarachnoid hemorrhage, [3] neonatal hypoxic-ischemic encephalopathy, [4] Down syndrome, and other neurological conditions.
How long does a treatment course last?
A standard treatment course consists of daily injections for 10-21 days. [10] For acute conditions like stroke or traumatic brain injury, treatment may extend up to 30 days. [10] For chronic neurodegenerative conditions such as Alzheimer's disease, treatment courses are typically repeated every 2-3 months, with a minimum of 4 courses per year recommended for sustained therapeutic benefit. Clinical studies show that repeated courses can produce cumulative cognitive improvements.
Can Cerebrolysin be combined with other Alzheimer's medications?
Yes, clinical evidence supports the combination of Cerebrolysin with cholinesterase inhibitors such as donepezil (Aricept). Studies have shown that this combination can enhance and prolong the therapeutic benefits compared to either treatment alone, particularly in moderate to advanced Alzheimer's disease. [1][15] Cerebrolysin may also be combined with memantine. However, any combination therapy should be managed by a qualified neurologist.
Is Cerebrolysin safe for individuals with pork allergies?
No. Cerebrolysin is derived from porcine (pig) brain tissue and is contraindicated in individuals with known hypersensitivity to porcine-derived products. [10][11][22] Patients with pork allergies or religious/dietary restrictions regarding pork products should not use this medication. An allergic reaction test or careful monitoring during the first administration may be advisable for patients with a history of allergies.
Further reading
History & related research
History · since 1949
A porcine brain extract that regenerates damaged neurons and restores cognitive function across 50+ countries.
Cerebrolysin is a standardized porcine brain-derived peptide preparation containing 80% low-molecular-weight peptides and 20% free amino acids. Developed in 1949 by Austrian neuropsychiatrist Gerhart Harrer, it contains fragments of neurotrophic factors including BDNF, GDNF, NGF, and CNTF.
Read the full history of CerebrolysinReady for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Cerebrolysin, on one page.